All In Biotech

Drugs by condition

Drugs approved for nausea and vomiting

Brand-name prescription drugs and biologics whose FDA label lists nausea and vomiting as an approved use. Matched on the label phrases: "nausea and vomiting".

Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

21

Still marketed, NDA or BLA

Drug classes

8

Novel drugs

10

New molecular entities and new biologics

In development

3

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for nausea and vomiting.

  • Navitrux (Fosaprepitant Dimeglumine) · Avyxa Holdings Jun 24, 2026
  • Focinvez (Fosaprepitant Dimeglumine) · Steriscience Aug 22, 2023
  • Aponvie (Aprepitant) · Heron Theraps INC NovelSep 16, 2022
  • Barhemsys (Amisulpride) · Lxo Ireland NovelFeb 26, 2020
  • Fosaprepitant Dimeglumine (Fosaprepitant Dimeglumine) · Teva Pharms USA Sep 5, 2019

All approved drugs for nausea and vomiting, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 177 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Substance P/Neurokinin-1 Receptor Antagonist (5)

  • Aponvie Aprepitant · Heron Theraps INC · 2022
  • Akynzeo Fosnetupitant Chloride Hydrochloride, Palonosetron Hydrochloride · Helsinn Hlthcare · 2018
  • Akynzeo Netupitant, Palonosetron Hydrochloride · Helsinn Hlthcare · 2014
  • Emend Aprepitant · Msd · 2003
  • Cinvanti Aprepitant · Heron Theraps INC · 2017

Aromatic Amino Acid Decarboxylation Inhibitor (2)

  • Sinemet Carbidopa, Levodopa · Organon · 1975
  • Lodosyn Carbidopa · Aton · 1977

Dopamine-2 Receptor Antagonist (1)

Cannabinoid (1)

  • Marinol Dronabinol · Alkem Labs LTD · 1985

Aminosalicylate (1)

Serotonin-3 Receptor Antagonist (1)

  • Sancuso Granisetron · Apotex · 2008

Anticholinergic (1)

Class not listed in FDA's data (9)

  • Varubi Rolapitant Hydrochloride · Tersera · 2015
  • Emend Fosaprepitant Dimeglumine · Merck and CO INC · 2008
  • Navitrux Fosaprepitant Dimeglumine · Avyxa Holdings · 2026
  • Focinvez Fosaprepitant Dimeglumine · Steriscience · 2023
  • Fosaprepitant Dimeglumine Fosaprepitant Dimeglumine · Teva Pharms USA · 2019
  • Bonjesta Doxylamine Succinate, Pyridoxine Hydrochloride · Duchesnay · 2016
  • Posfrea Palonosetron Hydrochloride · Avyxa Holdings · 2016
  • Diclegis Doxylamine Succinate, Pyridoxine Hydrochloride · Duchesnay · 2013
  • Tigan Trimethobenzamide Hydrochloride · Ph Health · 1974

Drugs in development for nausea and vomiting

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • HR20013Phase 31 trial

    Fujian Shengdi Pharmaceutical Co., Ltd. · Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents

  • HRS5580Phase 21 trial

    Fujian Shengdi Pharmaceutical Co., Ltd. · Prevention of Postoperative Nausea and Vomiting

  • Helsinn Healthcare SA · Nausea and Vomiting Chemotherapy-Induced, Nausea Post Chemotherapy

4 discontinued brand-name drugs whose label still names it

More on nausea and vomiting: recruiting trials · published research

Related in gastroenterology and liver: MASH (fatty liver disease) · Primary biliary cholangitis · Acid reflux (GERD) · Irritable bowel syndrome · Chronic constipation · Eosinophilic esophagitis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.